coiled-coil and HOOK domain protein 88AGenealiases: APE · GIRDIN · GIV · GRDN · HkRP1 · KIAA1212
Q-omics provides the consensus-scored CCDC88A profile across patient tissues and cancer cell-line models. CCDC88A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC88A is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CCDC88A protein abundance shows 22,277 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where CCDC88A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC88A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC88A survival associations across molecular data types. CCDC88A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC88A RNA expression–survival associations across cancer types. High CCDC88A expression shows unfavorable associations in ACC, MESO, LIHC, KIRP, UCEC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC88A RNA expression.
This table summarizes CCDC88A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC88A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC88A shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, KIRC, KIRP and LIHC. The HNSC box plot shows higher CCDC88A RNA expression in tumor versus normal tissue (log2 FC = +1.372, t-test p < 0.001).
This table shows molecular features associated with CCDC88A in patient tissues and cancer cell lines. In patient samples, CCDC88A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC88A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
